Objective To summarize the research progress of alternative splicing in pancreatic cancer, and to provide reference for further research. MethodThe experimental and clinical studies of alternative splicing in pancreatic cancer were reviewed.Results Alternative splicing dysregulation resulted in changed gene expression or novel isoform formation, thereby influencing the carcinogenesis, progression or chemoresistance of pancreatic cancer. The differentially expressed alternative splicing isoforms may serve as diagnostic markers, indicators of aggressiveness or prognostic markers of pancreatic cancer. Conclusion Further investigation of the molecular mechanisms of alternative splicing in carcinogenesis and progression of pancreatic cancer is a new way to improve the early diagnosis and treatment of pancreatic cancer.
